Buchumschlag

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Lesley A. Patmore, Milan J. Sonneveld
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
von: Danny Con
Veröffentlicht: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
von: Elisa Pinto, et al.
Veröffentlicht: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
von: Daniel Q. Huang, et al.
Veröffentlicht: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
von: Jonggi Choi
Veröffentlicht: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
von: Gamal Shiha, et al.
Veröffentlicht: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal
von: Edo J. Dongelmans, et al.
Veröffentlicht: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
von: Tanat Saeoui, et al.
Veröffentlicht: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
von: Rui Huang, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2026)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
von: Subin Heo, et al.
Veröffentlicht: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
von: Jiwon Yang, et al.
Veröffentlicht: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
von: Kuo‐Cheng Wu, et al.
Veröffentlicht: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
von: Sheila L. Noon, et al.
Veröffentlicht: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
von: Yuxin Chen, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
von: Xiao‐Dong Zhou, et al.
Veröffentlicht: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
von: Sarah Flatley
Veröffentlicht: (2026)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
von: Stefano Siboni, et al.
Veröffentlicht: (2026)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
von: Michelle Spaan, et al.
Veröffentlicht: (2026)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
von: Kaitlyn Carlson, et al.
Veröffentlicht: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
von: Ning Yu, et al.
Veröffentlicht: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
von: Jia‐Ling Wu, et al.
Veröffentlicht: (2025)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
von: Vincent Mallet, et al.
Veröffentlicht: (2025)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
von: Qin Ning, et al.
Veröffentlicht: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
von: Jiong Yu, et al.
Veröffentlicht: (2024)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
von: Grace Lai‐Hung Wong, et al.
Veröffentlicht: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
von: Maria Buti
Veröffentlicht: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Shinya Yokoyama, et al.
Veröffentlicht: (2025)